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The purpose of this study was to evaluate financial 
impact of a regional cost saving initiative by the 
antimicrobial stewardship program for all acute care 
facilities within the region, and identify potential 
areas to reduce costs in the future.
The study looked at the following: 
• Cost savings associated with reduced extended-
infusion piperacillin/tazobactam administrations in 
2020.
• Difference in overall days of therapy and 
antimicrobial-associated costs between 2019-2020.
• Cost savings associated with decrease in use of 
restricted antimicrobial agents between 2019-2020.
• Potential cost savings associated with reduction in 
hospital length of stay related to extended-infusion 
cefepime use in ICU patients for the treatment of 
Pseudomonas aeruginosa pneumonia.  
• The initiative by the antimicrobial stewardship 
program has resulted in substantial cost savings 
for all covered inpatient facilities within the 
region.
• In 2020, the use of extended-infusion 
piperacillin/tazobactam resulted in saving 
$226,420 due to reduced administrations 
compared to traditional infusion. 
• Decreased usage in antimicrobial agents that 
have been considered as “restricted” by the 
antimicrobial stewardship team resulted in 
$182,837 saved in 2020. 
• Overall, $616,178 was saved in antimicrobial 
costs in 2020, after excluding costs attributed to 
remdesivir, due to 19,775 days reduction in 
overall days of therapy per 1000 patient days 
between 2019 and 2020. 
• For patients who are admitted to the ICU for 
pneumonia due to P. aeruginosa requiring 
cefepime administration, transition to extended-
infusion cefepime is anticipated to save between 
$138,584.25-$1,385,842.5 depending on LOS 
reduction between 1-10 days
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Health & Services
• Since 2017, antimicrobial stewardship is a Centers 
for Medicare & Medicaid Services (CMS) and The 
Joint Commission (TJC) requirement for all acute 
care hospitals, critical access hospitals, and 
nursing care centers. 
• Given the current evidence supporting the 
utilization of extended-infusion beta-lactams, the 
system transitioned all its acute care facilities 
within the region to extended-infusion 
piperacillin/tazobactam (TZP) in March 2016 
• According to Bauer et al, the median length of 
stay and hospital costs were significantly less for 
patients admitted to the ICU who received 
extended-infusion cefepime for bacteremia and/or 
pneumonia
Methods
• Multi-site retrospective review of eight inpatient 
medical centers within the region of a large 
integrated healthcare system
• Cost of each TZP premix bag was $10
• Cost of each hospitalized day in 2020, excluding 
COVID-associated expenses was between 
$3611.16 - $8392.71/day, depending on facility 
• Cost difference between 2019 and 2020 
associated with change in usage of pre-specified 
“restricted” antimicrobial agents, as well as total 
costs and days of therapy associated with 
overall antimicrobial usage, excluding for 
remdesivir, were collected through Tableau 
reporting system
Extended-infusion can optimize the time-
dependent property of beta-lactams without the 
need for increased dose or more frequent 
administrations, therefore minimizing risk for 
development of adverse events. Given the 
growing prevalence of multidrug-resistant 
pathogens, optimizing the pharmacokinetic and 
pharmacodynamic parameters of current 
antibiotics to improve therapeutic efficacy is 
prudent in improving clinical outcomes, while 
maintaining antimicrobial sensitivity in the 
community and minimizing unnecessary costs. 
Based on current literature, the transition to 
extended-infusion cefepime in the treatment of P. 
aeruginosa pneumonia in patients requiring ICU 
admission may reduce hospital costs.
Figure 1. Cost savings associated with extended-infusion piperacillin/tazobactam in 2020
Results
Figure 2. Cost savings associated with reduced restricted agents usage between 2019-2020
Figure 3. Regional overall antimicrobial cost savings in 2020 (excluding remdesivir-associated)
Table 1. Costs associated with hospital LOS in patients admitted to ICU on cefepime for Pseudomonas 
pneumonia in 2020
Hospital A Hospital B Hospital C Hospital D Hospital E Hospital F Hospital G Hospital H TOTAL
2019 $32,603.00 $366,128.00 $134,436.00 $108,683.00 $1,547,536.00 $49,060.00 $1,542,989.00 $150,305.00 $3,931,740.00








































































Facility Cost per LOS day Mean LOS Total LOS costs
Hospital B $5,773.1 17 $98,142.70
Hospital C $3,611.16 2 $7,222.32
Hospital E $8,392.71 27 $226,603.17
Hospital G $5,594.49 31 $173,429.19
Hospital $4,345.39 11 $47,799.29
Regional (n=25) $5,543.37 18 $110,639.33
ATM NAF PRV AMB CPT CZA C/T DAP ETP FDX LZD POS Other Total
2019 $23,583. $65,167. $25,470. $87,614. $69,897. $12,805. $6,842.0 $141,660 $21,086. $18,369. $12,461. $78,442. $8,989.0 $563,396
2020 $13,894. $60,732. $2,151.0 $52,801. $64,839. $17,486. $9,606.0 $65,504. $10,814. $21,023. $11,571. $48,481. $10,646. $378,902
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